Targeting Major
Cancer Markets
Edison Oncology was founded in 2018 by experienced life science industry veterans to develop and commercialize new therapies targeting the fight against cancer.
Identifying and Advancing Underdeveloped Candidates
By leveraging our deep understanding of tumor biology and translational drug development expertise, we seek to identify and acquire select underdeveloped drug candidates, and specifically target them to patients whose tumors are most likely to respond to therapy.
Developing Disruptive Drug Candidates
We are developing a pipeline of unique small-molecule product candidates, each with several “shots on goal” in both orphan and major cancer markets. Our goal is to address unmet medical needs and improve the lives of cancer patients whose tumors harbor mutations known to be targeted by our product candidates.
Our Approach to Improve Cancer Patient Outcomes
Cancer results from mutations that fundamentally alter the properties of normal cells and allow tumors to form, grow, metastasize, and evade treatment. We aim to improve outcomes for cancer patients by leveraging a deep understanding of tumor biology and cancer pharmacology to identify and advance underdeveloped drug candidates.
Business Development Opportunities
Please contact us if you are interested in business opportunities.
Careers
Join our team! Visit our website to view available opportunities and apply now.
Investors
All prospective investors, please contact us if you are interested in learning more.
No posts were found for provided query parameters.